Clinical Trials Logo

Heparin-Induced Thrombocytopenia clinical trials

View clinical trials related to Heparin-Induced Thrombocytopenia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03809481 Terminated - Clinical trials for Heparin-induced Thrombocytopenia

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

HITSOVA
Start date: May 16, 2019
Phase: Phase 3
Study type: Interventional

An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)

NCT ID: NCT03594045 Terminated - Clinical trials for Heparin-induced Thrombocytopenia

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

Start date: December 18, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in this study is apixaban.

NCT ID: NCT01598168 Terminated - Clinical trials for Heparin-induced Thrombocytopenia

Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia

Start date: January 2013
Phase: Phase 3
Study type: Interventional

Heparin is an anticoagulant (blood thinner) that is commonly used to treat patients with heart attacks and patients with blood clots in their legs or lungs (venous thrombosis). Some patients develop an allergic reaction to heparin, a condition called heparin-induced thrombocytopenia (HIT). HIT makes blood clot, which is the opposite of what heparin was designed to do. These blood clots can lead to heart attacks, strokes, limb amputations, and death. The objective of this 200 patient study is to determine if a new blood thinner called rivaroxaban (Xarelto) can be used to treat HIT. Rivaroxaban can be taken by mouth, does not require blood testing, and had a low risk of bleeding when it was used to treat blood clots in other clinical trials. If this study shows that rivaroxaban can be used to treat HIT, there will be two very important benefits. For patients with HIT, the benefit will be having a safe, and easy-to-use drug to protect them from developing further life or limb-threatening blood clots. For the Canadian health care system, the benefit will be having a drug that is much less expensive than the drugs currently used to treat HIT.

NCT ID: NCT00673439 Terminated - Clinical trials for Heparin-Induced Thrombocytopenia

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine how safe and effective fondaparinux is in treating patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).